All Blogs

Feb 24, 2022

Use of CAR-T treatments and their efficacy in Prostate Cancer We already know that Immunotherapies have not performed well in the treatment of prostate cancer. Such medicines have failed to elicit a long-term response in patients with advanced prostate cancer. Surgery, radiation treatment, chemotherapy, androgen...

Feb 24, 2022

Major Key player Arvinas announced completed Phase I and interim Phase II ARDENT data for ARV-110 degrader targeting the androgen receptor (AR). According to the results, Arvinas mentioned that at the data cut-off date, December 20, 2021, the PSA50 response rate was 46% in 28 patients with AR T878X/H875Y tumor muta...

Feb 24, 2022

US FDA grants 510(k) clearance to Motus GI’s Pure-Vu EVS System On February 15, 2022, The Pure-Vu® EVS System received 510(k) clearance from the US Food and Drug Administration, according to Motus GI Holdings, Inc., a medical technology company that provides endoscopy solutions that improve clinical outcomes and...

Feb 23, 2022

Adrenal Crisis refers to overwhelming and life-threatening adrenal insufficiency. The most common signs of Adrenal Crisis are shocking (very low blood pressure with a loss of consciousness), dehydration, and an imbalance of sodium and potassium levels in the body. In some cases, shock is then preceded by several ot...

Feb 22, 2022

Sandoz Launches generic Revlimid in 19 European Countries, Bringing a Flood of Competition to BMS' Megablockbuster Since Bristol Myers Squibb acquired Celgene and its megablockbuster Revlimid, the company has been bracing for the day when the multiple myeloma superstar would face generic competition. Sandoz, a s...

Feb 22, 2022

According to the findings of the ARASENS trial (NCT02799602), presented by Bayer at the 2022 ASCO GU, Nubeqa resulted in a 32.5% reduction in the risk of death, with a median follow-up of 43.7 months for darolutamide.  Nubeqa provided a consistent overall survival advantage across predefined subgroups. The med...

Feb 22, 2022

Preliminary findings of Phase I/II dose-expansion study of DS-7300 (a B7-H3 antibody-drug conjugate) in mCRPC patients backed B7-H3 as a potential new target in treatment-resistant prostate cancers (Abstract #87) Immune-checkpoint inhibitors (ICI) have resulted in significant therapeutic advancements in a wide r...

Feb 21, 2022

Delveinsight brings you the comparative analysis on Positive Phase III trial results of PARP inhibitors, Zejula (Niraparib) and Lynparza (Olaparib) in metastatic CRPC patient population. PARP inhibitors are one of the most promising therapeutic classes in the phase III pipeline, based on the demonstrated effecti...

Nov 01, 2024

A Neuroendocrine tumor is a type of cancer where neuroendocrine cells develop into tumors. Whereas Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) are tumors that arise from neuroendocrine cells in the gut. A Neuroendocrine Tumor grows slowly and aggressively and tends to spread to other parts of the body. ...

Aug 23, 2024

Duchenne Muscular Dystrophy (DMD) is a rare disorder, but it is one of the most common genetic conditions, affecting roughly 1 in every 3,500 male births worldwide. Gene therapy for Duchenne Muscular Dystrophy (DMD) is poised to revolutionize the treatment landscape by addressing the underlying genetic cause of the...